Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Ebola Virus Disease Vaccine Phase II Trial
CTR20150673Phase 2Active
- Sponsor
- Beijing Institute of Biotechnology
- Start
- Oct 2015
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of Ad5-EBOV in Ebola virus disease (EVD), sponsored by Beijing Institute of Biotechnology. Started Oct 2015; status: active.
02
Drugs
Ad5-EBOV
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on CTR20150673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150673.